Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | FCER2 | P06734 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989218 | 1.00 | EPHX1 (0.53) | EPHX1TAAR1FCER2MMP1SLC18A2 | |
| SCHEMBL13711063 | 1.00 | EPHX1 (0.53) | EPHX1TAAR1FCER2MMP1SLC18A2 | |
| Hydrochloric Acid SCHEMBL6895586 | 0.98 | EPHX1 (0.51) | EPHX1TAAR1FCER2MMP1SLC18A2 | |
| Trifluoroacetic Acid SCHEMBL21065923 | 0.92 | PTPN1 (0.46) | EPHX1TAAR1FCER2MMP1SLC18A2 | |
| Trifluoroacetic Acid SCHEMBL7268669 | 0.92 | PTPN1 (0.46) | EPHX1TAAR1FCER2MMP1SLC18A2 | |
| SCHEMBL17550583 | 0.89 | FCER2 (0.57) | FCER2MMP1HPGDS | |
| SCHEMBL8175870 | 0.87 | TAAR1 (0.52) | TAAR1SLC18A2SIGMAR1NPC1RAB9A | |
| SCHEMBL2628426 | 0.87 | TAAR1 (0.52) | TAAR1SLC18A2SIGMAR1NPC1RAB9A | |
| SCHEMBL8318346 | 0.87 | TAAR1 (0.52) | TAAR1SLC18A2SIGMAR1NPC1RAB9A | |
| SCHEMBL17550603 | 0.86 | FCER2 (0.49) | FCER2MMP1HPGDSPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186634-A1 | METHODS OF TREATING SMALL CELL LUNG CANCER | Evergreen Discovery, LLC (US) | 2025-06-12 | — | — | US | claimed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | claimed |
| JP-63123398-A | — | — | None | — | — | JP | disclosed |
| JP-63160599-A | — | — | None | — | — | JP | disclosed |
| JP-57186495-A | — | — | None | — | — | JP | disclosed |
| CN-117186189-A | GLP-1/CCK-1 receptor double-excitation polypeptide with hypoglycemic and weight-reducing effects and application thereof | 嘉兴学院 | 2023-12-08 | — | — | CN | disclosed |
| US-20230312646-A1 | ANTIBACTERIAL PEPTIDES | Universite de Bordeaux (FR) | 2023-10-05 | — | — | US | disclosed |
| US-20230312646-A1 | ANTIBACTERIAL PEPTIDES | Universite de Bordeaux (FR) | 2023-10-05 | — | — | US | disclosed |
| WO-2023172641-A2 | TARGET SUBSTRATE PROTEIN DEGRADATION PLATFORM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-4137496-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Beijing Greatway Pharmaceutical Technology Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| EP-4092038-A1 | OPIOID AGONIST PEPTIDES AND USES THEREOF | Protagonist Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-0417217-A1 | PEPTIDES WITH SULPHATE ESTER GROUPS | FISONS CORPORATION (US) | 1991-03-20 | — | — | EP | disclosed |
| WO-1990008773-A1 | PEPTIDES WITH SULPHATE ESTER GROUPS | FISONS CORPORATION (US) | 1990-08-09 | — | — | WO | disclosed |
| EP-0376012-A2 | Renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| EP-0376040-A2 | N-phosphinyl di-and tripeptides as renin inhibitors | AMERICAN CYANAMID COMPANY (US) | 1990-07-04 | — | — | EP | disclosed |
| JP-S63160599-A | PRODUCTION OF L-ALPHA-METHYLPHENYLALANINES | MITSUBISHI GAS CHEM CO INC | 1988-07-04 | — | — | JP | disclosed |
| JP-S63123398-A | PRODUCTION OF L-ALPHA-METHYLPHENYLALANINES | MITSUBISHI GAS CHEM CO INC | 1988-05-27 | — | — | JP | disclosed |
| EP-0224151-A2 | 2-Substituted-[2-substituted-amino]-N-aralkyl-3-[indol-3-yl]propanamides | WARNER-LAMBERT COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
| JP-S57186495-A | PREPARATION OF L-ALPHA-METHYLPHENYLALANINE | UBE IND LTD | 1982-11-16 | — | — | JP | disclosed |
| EP-0001684-A2 | Tetrapeptides, methods for their preparation and their use in analgesic compositions | ELI LILLY AND COMPANY (US) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | EPHX1 3252/4885TAAR1 1981/4885FCER2 357/4885 |
| US-20250186634-A1 | METHODS OF TREATING SMALL CELL LUNG CANCER | SSTR2, CCKBR, GRPR | EPHX1 4347/4885TAAR1 332/4885FCER2 615/4885 |
| US-20230312646-A1 | ANTIBACTERIAL PEPTIDES | VIP, NRDC, CLPP | EPHX1 4486/4885TAAR1 4854/4885FCER2 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.